We are pleased to announce the entry of the Galia Gestion fund and the majority entry by the historical management, Mr. Arnaud Cardinet into the capital of Gabilly Company (now Lyamtech).
Gabilly company specializes in a niche of diagnostics, manufacturing, and support in light medical equipment. It primarily addresses mobility-impaired patients on medical prescription. Gabilly is one of the major players in its segment.
The manager can now support the very strong development potential of his offer. This potential is deployed through the development of a network, the expansion of a product range, and the exploitation of new innovative technologies.
I-Deal Development was able to meet the expectations of Gabilly’s management by taking into account the complexity of the shareholding and the interests of the family context. A development strategy was built alongside the manager, emphasizing the intrinsic characteristics of the market.
The Galia fund, a capital investor, is a preferred shareholder of regional “human-sized” companies, with a minority support strategy.
While allowing the current manager to focus on his activity, I-Deal Development was able to build a tailor-made solution with the managers of Gabilly and Galia (new shareholder).
